Dexcom Inc (NASDAQ: DXCM)

DexCom, Inc. is a medical device company focused on the design development and commercialization of continuous glucose monitoring systems for diabetes and metabolic health management. The company received FDA approval for its first product in 2006 and has since launched multiple generations of CGM systems including the G7 in 2023 and the G7 15 Day in late 2025. In August 2024 DexCom introduced Stelo the first over the counter glucose biosensor in the United States aimed at adults with prediabetes and type 2 diabetes who do not use insulin. DexCom operates globally with presence in North America Africa Asia Pacific Europe Latin America and the Middle East and employs approximately eleven thousand one hundred people as of December 31 2025. The company's mission is to empower people with diabetes and those seeking to optimize metabolic health to manage their glucose levels more effectively and conveniently through innovative wearable technology.

The company generates revenue primarily from the sale of continuous glucose monitoring hardware such as sensors transmitters and receivers. Associated software and services including Dexcom Share remote monitoring and data analytics also contribute to sales. Income is earned from collaborations with insulin delivery partners that integrate its CGM technology with partner devices to enable semi automated insulin delivery and data sharing. Sales of the over the counter biosensor Stelo add to revenue especially among individuals with prediabetes and type 2 diabetes who do not use insulin. DexCom uses a direct sales force in North America and selected international markets and relies on distribution arrangements in other regions to reach health care professionals and patients. Marketing efforts include direct to consumer advertising via television print digital media and participation in diabetes related events to drive awareness and adoption. The company also benefits from manufacturing facilities in Mesa Arizona Penang Malaysia and a new facility under construction in Athenry Ireland which support product supply and help meet global demand.

DexCom holds a leading position in the continuous glucose monitoring market competing primarily with Abbott Laboratories FreeStyle Libre Medtronic Guardian Connect and Simplera Roche Diabetes Care LifeScan and Ascensia Diabetes Care. The company's competitive advantages stem from high accuracy and reliability of its sensors ease of use and comfort of the wearable design strong brand recognition among patients and clinicians broad reimbursement coverage from Medicare Medicaid and private insurers and a rapid pace of innovation. DexCom benefits from its extensive patent portfolio and regulatory expertise which support timely product launches and sustained technological leadership. The firm continues to invest in research and development to expand its product pipeline and improve sensor performance algorithm accuracy and integration capabilities with digital health platforms and insulin pumps. These efforts aim to maintain its edge in a market characterized by intense competition and rapid technological change.

DexCom serves individuals with type 1 and type 2 diabetes caregivers clinicians and individuals seeking to manage metabolic health including those with prediabetes. The company also works with health care providers and payors such as Medicare Medicaid and private insurers to obtain coverage and reimbursement for its products. Its products are used by patients in home care settings and by health care professionals in clinics and hospitals across the United States and internationally. DexCom reports that its customer base includes a growing number of people with type 2 diabetes who do not use insulin but seek better glucose control through over the counter options like Stelo. The company also supports caregivers and family members through its Dexcom Share and Follow remote monitoring system which allows up to ten designated recipients to view glucose data and receive alerts. Additionally DexCom collaborates with health care organizations to provide data insights that help improve diabetes management programs and patient outcomes.